|
National Lung Cancer Partnership has supported the following lung cancer research programs:
Career Development Awards for junior clinical and basic investigators involved in lung cancer etiology, prevention, and treatment.
Research Grants designed to provide seed money for promising novel research in lung cancer for faculty members at any point in their careers. This award promotes understanding the molecular, cellular, and environmental underpinnings of lung cancer, as well as differences in response to treatment, with a special emphasis on understanding sex differences in the disease.
Career Development Award
Research Grant
Other Grant Partnerships
2009:
 I-Ching Wang, PhD, Cincinnati Children's Hospital Medical Center
Dr. Wang seeks to understand how FoxM1, a protein that helps regulate cell growth in normal cells, may also contribute to uncontrolled growth in cancerous cells. Although FoxM1 is known to play a role in the development of lung cancer, the exact mechanisms by which it is acting are not yet defined. Dr. Wang’s research seeks to define FoxM1’s actions in lung cancer initiation, ultimately to help facilitate development of novel therapies directed towards the protein.
2008:
 Adam Marcus, PhD, Winship Cancer Institute at Emory University
Dr. Marcus is seeking to understand how lung cancer cells are able to invade surrounding tissues.
2007 (with LUNGevity Foundation):
 Michele Cote, PhD, Karmanos Cancer Institute at Wayne State University
Dr. Cote is pursuing research investigating the role of estrogen-related tumor characteristics in predicting survival after a lung cancer diagnosis, and in particular, the relationship between estrogen expression and survival in individuals who get lung cancer before they are 50 years old.
2005 (with The Lung Cancer Online Foundation):
 Hayley McDaid, PhD, Albert Einstein College of Medicine of Yeshiva University
Dr. McDaid investigated how lung cancer cells respond to new classes of drugs that specifically target the dysfunctional growth of cancer cells, and how the cells become resistant to the effects of these drugs.
To view an article about Dr. McDaid's research funded by this grant click here.
2009 (with LUNGevity Foundation):
 Prasad Adusumilli, MD, Memorial Sloan-Kettering Cancer Center
Dr. Adusumilli aims to improve treatment for patients with Visceral Pleural Invasion, a condition that affects one in four early stage lung cancer patients, where cancer cells spread to the membrane covering the lungs’ surface. The goal of his research is to develop a novel lung cancer treatment by genetically modifying patients’ own immune cells (T cells) to eliminate their tumor cells.
 Lee Goodglick, PhD, University of California, Los Angeles
Dr. Goodglick will focus on how estrogen may drive some lung tumors to grow and become more deadly. Aromatase-inhibitor drugs, which have long been used to treat breast cancer by decreasing estrogen levels in patients, will be studied in pre-clinical models to determine their effectiveness in treating lung cancer. Additional research will use new technologies to study lung tumor tissues to determine other steps in the estrogen stimulation pathway that affect tumor progression.
2008 (with LUNGevity Foundation):
 Hildegard Schuller, DVM, PhD, University of Tennessee
Dr. Schuller's research will evaluate the relationship between estrogen and the nicotine-derived carcinogen, NNK, in lung tumor foundation.
 Albert Baldwin, PhD, Lineberger Cancer Center at the University of North Carolina at Chapel Hill
Dr. Baldwin is investigating genetic and molecular changes that can transform normal cells into cancer cells.
2007:
 Richard Pietras, PhD, MD, UCLA
Dr. Pietras is studying how estrogen, estrogen receptors, and other molecules that interact with the estrogen receptor complex work together to stimulate lung tumor growth.
To view an article about Dr. Pietras' research funded by this grant click here.
2005:
 Christoph Plass, PhD, The Ohio State University
Dr. Plass investigated how lung tumor tissues from males and females differ in the way that DNA is modified within the cancerous cells. His research focuses on the involvement of estrogen in the modification of DNA, and whether these modifications may lead to the numerous sex differences seen in lung cancer.
To read two articles about Dr. Plass' research funded by this grant click here and here.
To read a press release on Dr. Plass' research click here.
2009:
 Janette Vardy, MD, PhD, University of Sydney in Sydney, Australia
Dr. Vardy will determine if a physical activity program will help improve fatigue, quality of life, and overall physical function for patients with advanced-stage lung cancer. This study has the potential to change standard of care for lung cancer patients by adding physical activity as a non-toxic, inexpensive treatment option, which could improve patients’ quality of life.
2008:
 Grace Dean, PhD, RN and Suzanne Dickerson, DNS, State University of New York - University at Buffalo School of Nursing
Drs. Dean and Dickerson seek to better understand the sleep disturbances lung cancer patients experience, in order to improve sleep and overall quality of life for lung cancer patients during their treatment and beyond.
2008:
 Ilse Valencia, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center
Dr. Valencia is seeking to understand how some non-small-cell lung cancer (NSCLC) tumors become resistant to drugs like erlotinib (Tarceva) that target the epidermal growth factor receptor (EGFR).
|
 |
|
|
My Beautiful Mama
By: Susan Grizzelle
In March of 2006, my beautiful mom was diagnosed with stage IIIB lung cancer. This disease strikes without warning - my mom was 59 when she was diagn...
More >> |
|
|
|
We are a beneficiary of GoodSearch – a search engine designed to give back to non-profits. Visit www.GoodSearch.com and type in “lung cancer” in the “I’m supporting” field, then click on “National Lung Cancer Partnership.” Every time you use GoodSearch to search the internet, we get a penny! |
|
|
|
|
|
|
|
